中文 English

OncoAim® Lung Cancer RNA Fusion Gene Detection Assay

Detection method

The next-generation sequencing (NGS) used in this assay, compared to PCR and Sanger sequencing methods, is able to simultaneously detect mutations in multiple genes or regions. A single test can provide more information on clinical diagnosis and treatment.

Test significance

To provide guidance for targeted drugs related to common gene fusions in non-small cell lung cancer.

Product advantage

- Overcomes detection errors caused by differences in breakpoint positions between fusion genes in the genome. 

- Avoids an excessive amount of DNA sequencing data, resulting in improved sequencing depth and data analysis efficiency.

- Detects gene fusions for successful transcription of highly expressed RNA variants and predicts abnormal gene function, which is relevant to the selection of treatment options.

- Compared with traditional method (FISH), patients positive for fusion genes are more likely to benefit from targeted drugs.

Detection of genes

Tumor genes(4)

  • ALK
  • ROS1
  • RET
  • NTRK1

Applicable to cancer patients

- Lung cancer patients treated with targeted medication. The assay will identify the patients with the most benefits of certain targeted treatments.

Test procedure

*Product is for research use only.